Single Cell Multiomics Market to Reach US$ 5.21 Billion by 2031 at 21.2% CAGR | North America Leads with 48% Share | Key Players: 10x Genomics, BD Biosciences, Illumina

The global single cell multiomics market reached US$ 1.25 billion in 2023 and is projected to reach US$ 5.21 billion by 2031, growing at a CAGR of 21.2% during the forecast period 2024-2031. The market is expanding rapidly due to rising demand for high-resolution cellular analysis in biomedical research, precision medicine, oncology, immunology, and drug development. Single cell multiomics enables simultaneous analysis of genetic, transcriptomic, proteomic, and epigenetic data from individual cells, offering deeper insights into cellular heterogeneity, disease mechanisms, and treatment response. Continuous advancements in next-generation sequencing, microfluidics, and computational platforms are strengthening adoption across pharmaceutical companies, biotech organizations, and academic research centers.

Growing investments in genomics programs, biomarker discovery, and personalized therapeutics are further driving market growth. Applications in early disease detection, immune profiling, and stem cell research are expanding rapidly, supported by increased funding from both public and private sectors. While North America leads due to robust infrastructure and large-scale research initiatives, the Asia Pacific region is emerging as a high-growth market driven by rising healthcare innovation, expanding research capabilities, and government-backed genomics initiatives.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/single-cell-multiomics-market?sai-v

The single cell multiomics market refers to the industry developing technologies that analyze multiple molecular layers, such as genomics, transcriptomics, proteomics, and epigenomics, at the single-cell level to provide deeper biological insights.

Key Developments
✅ October 2025: U.S. genomics companies expanded deployment of high-throughput single-cell platforms integrating transcriptomics, epigenomics, and proteomics to accelerate precision medicine and oncology research.

✅ September 2025: European research institutes adopted next-generation microfluidics systems enabling multi-layer omics profiling from ultra-low-input samples, boosting rare-cell population analysis.

✅ August 2025: Asia-Pacific biopharma companies integrated AI-driven multiomics data analytics pipelines to improve drug discovery workflows for immune-oncology and metabolic diseases.

✅ July 2025: Global sequencing leaders introduced advanced library preparation kits that reduce per-cell processing costs while improving data depth and multiomic coverage.

✅ May 2025: Innovations in spatial multiomics platforms allowed researchers to map gene expression, protein signatures, and chromatin states simultaneously within intact tissue environments.

✅ March 2025: Academic and clinical labs worldwide scaled adoption of single-cell multiomics for biomarker discovery, disease stratification, and early diagnostics across oncology, neurology, and immunology.

Mergers & Acquisitions
✅ November 2025: A major U.S. single-cell technology developer acquired a European computational biology firm to strengthen its multiomics data-integration and AI-analytics capabilities.

✅ August 2025: A global sequencing company partnered with a microfluidics startup to co-develop ultra-high-throughput platforms for multiomic single-cell measurements.

✅ June 2025: A North American life sciences group acquired a specialized spatial-omics technology company to expand its multiomic imaging and tissue-mapping portfolio.

Key Players
10x Genomics Inc. | BD Biosciences | Berkeley Lights Inc. | Cytena | Dolomite Bio | Fluidigm Corporation | Illumina Inc. | NanoString Technologies Inc. | QIAGEN N.V. | Takara Holdings Inc.

Key Highlights
10x Genomics Inc. - Holds 17.2% share, driven by its leadership in single-cell analysis platforms, high-throughput sequencing solutions, and rapidly expanding multi-omics portfolio.

BD Biosciences - Holds 14.6% share, supported by its strong flow cytometry product line, advanced cell sorting systems, and global clinical research collaborations.

Berkeley Lights Inc. - Holds 9.3% share, fueled by its innovative optofluidic cell manipulation technology and growing adoption in cell line development.

Cytena - Holds 6.8% share, driven by its expertise in single-cell dispensing systems and rising usage in biopharmaceutical R&D.

Dolomite Bio - Holds 5.9% share, supported by its microfluidics-based single-cell solutions and increasing applications in genomics research.

Fluidigm Corporation - Holds 8.7% share, backed by its CyTOF mass cytometry systems, genomics tools, and broad life sciences customer base.

Illumina Inc. - Holds 13.4% share, driven by its dominant position in sequencing technologies that complement single-cell workflows and multi-omics applications.

NanoString Technologies Inc. - Holds 10.1% share, fueled by its spatial genomics platforms, digital profiling tools, and strong oncology research demand.

QIAGEN N.V. - Holds 7.6% share, supported by its sample preparation, NGS workflow integration, and expanding single-cell analysis portfolio.

Takara Holdings Inc. - Holds 6.4% share, driven by its high-performance reagents, single-cell library prep kits, and strong global research community presence.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=single-cell-multiomics-market?sai-v

(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Growing demand for high-resolution cellular analysis to understand complex biological systems, disease progression, and cellular heterogeneity.

• Increasing adoption of single-cell sequencing technologies in oncology, immunology, neurology, and developmental biology.

• Rising investment in precision medicine and biomarker discovery driving need for integrated multiomic datasets.

• Advancements in single-cell platforms enabling simultaneous analysis of genomics, transcriptomics, epigenomics, and proteomics.

• Rapid expansion of cancer research, including tumor microenvironment profiling and minimal residual disease detection.

• Growing usage of AI and computational tools for multiomic data integration, interpretation, and pathway mapping.

• Increased funding from governments, pharma companies, and academic institutes for single-cell research programs.

• Expanding applications in drug discovery, cell therapy development, and regenerative medicine.

Industry Developments
• Launch of next-generation multiomic platforms capable of whole-genome, methylation, and protein-level analysis at single-cell resolution.

• Development of high-throughput single-cell sequencing systems enabling large-scale studies at reduced cost.

• Growing collaborations between technology companies, pharma firms, and research institutes to accelerate multiomic insights.

• Integration of spatial transcriptomics and spatial proteomics with single-cell analysis.

• Expansion of computational multiomics pipelines using machine learning and cloud-based analytics.

• Increased commercialization of single-cell sample preparation kits, microfluidic chips, and multiomic assay technologies.

• Rising number of multiomic biobanks and reference atlases for disease-specific research.

• Growing focus on single-cell multiomics in immuno-oncology, including T-cell profiling and response prediction.

Regional Insights
North America - 48% share: "Driven by strong genomic research funding, rapid adoption of advanced single-cell technologies, and high presence of biotech innovators."

Europe - 30% share: "Supported by extensive academic research networks, government-funded multiomic initiatives, and growing adoption in oncology and immunology studies."

Asia Pacific - 18% share: "Fueled by increasing genomic research investments, expanding biotech ecosystems, and rising use of single-cell tools in China, Japan, and South Korea."

Latin America - 3% share: "Boosted by growing research collaborations, improving bioinformatics capabilities, and increasing participation in global genomics programs."

Middle East & Africa - 1% share: "Driven by emerging genomic medicine initiatives, growing healthcare modernization, and increasing investment in advanced research infrastructure."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/single-cell-multiomics-market?sai-v

Key Segments

➥ By Type
Single Cell Genomics: Focuses on DNA-level analysis of individual cells to study mutations, genetic heterogeneity, gene regulation, and genome architecture, widely used in cancer evolution and rare-cell detection.

Single Cell Proteomics: Analyzes protein expression at a single-cell level, enabling insights into signaling pathways, cellular function, and protein-protein interactions with high sensitivity.

Single Cell Transcriptomics: Examines RNA transcripts within individual cells to understand gene expression patterns, cellular states, and microenvironment interactions, crucial for immune profiling and developmental biology.

Single Cell Metabolomics: Profiles metabolites in single cells to uncover metabolic diversity, pathway behavior, and real-time biochemical activity, supporting precision medicine and disease mechanism studies.

➥ By Application
Oncology: Used to study tumor heterogeneity, drug resistance, mutation profiles, and rare cancer cell populations for personalized cancer therapy.

Cell Biology: Supports understanding of cell differentiation, signaling mechanisms, cellular responses, and developmental processes at individual-cell resolution.

Neurology: Enables mapping of neuronal diversity, neural circuit behavior, and mechanisms behind neurodegenerative diseases such as Alzheimer's and Parkinson's.

Immunology: Facilitates deep immune profiling, T-cell/B-cell characterization, immune response dynamics, and discovery of novel immunotherapy targets.

Stem Cell Research: Used to track stem cell differentiation, regeneration pathways, and pluripotency markers for regenerative medicine and therapeutic development.

➥ By Technique
Single-Cell Isolation & Dispensing: Techniques such as FACS, microfluidics, laser capture microdissection, and manual picking used to isolate individual cells with high precision for downstream analysis.

Single-Cell Analysis: Includes sequencing, imaging, proteomic and metabolic profiling methods to decode genomic, transcriptomic, and functional characteristics at a single-cell level.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.